Spots Global Cancer Trial Database for HRD and Resistance to PAPPi in EOC Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: HRD and Resistance to PAPPi in EOC Patients

Official Title: Correlation Between Homologous Recombination Deficiency Status and Resistance to PARP Inhibitors in Chinese Epithelial Ovarian Cancer Patients

Study ID: NCT05310370

Conditions

Epithelial Ovarian Cancer

Homologous Recombination Deficiency

Homologous Recombination Repair Gene Mutation

Poly(ADP-ribose) Polymerase Inhibitor

Drug Resistance

Progression-free Survival

Overall Survival

Interventions

Testing of homologous recombination deficiency

Study Description

Brief Summary: The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667 and NCT04651920). This study is to investigate the correlation between HRD and the resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) in a Chinese cohort confirmed of epithelial ovarian cancer. The mutated genes, HRD score model and their relationship with the prognosis is the primary endpoint in this study. All enrolled patients will accept PARPi as maintenance therapy after the complete or partial remission of targeted lesions. A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.

Detailed Description: